Compositions and methods for the treatment and prevention of hyperproliferative diseases
View Patent ↗Monotherapies and combination therapies for treating hyperproliferative disorders are described, as are compositions for performing such methods.
1. A method for treating an S1P-associated hyperproliferative disease associated with aberrant cardiac remodeling, comprising administering to a mammal known or suspected to suffer therefrom a therapeutically effective amount of an anti-S1P antibody to lower the effective concentration of S1P in the mammal, thereby treating the S1P-associated hyperproliferative disease associated with aberrant cardiac remodeling.
2. A method according to claim 1 wherein the S1P-associated hyperproliferative disease associated with aberrant cardiac remodeling is cardiac failure.
3. A method according to claim 1 wherein the S1P-associated hyperproliferative disease associated with aberrant cardiac remodeling is restenosis.
4. A method according to claim 1 wherein the mammal is selected from the group consisting of bovine, canine, equine, ovine and porcine animals.
5. A method according to claim 1 wherein the mammal is human.
6. A method according to claim 1 wherein the anti-S1P antibody is part of a composition that further comprises a carrier, optionally a pharmaceutically acceptable carrier.
7. A method according to claim 1 wherein the composition comprising the anti-S1P antibody is administered as a monotherapy.
8. A method according to claim 1 wherein the composition comprising the anti-S1P antibody is administered as part of a combination therapy.
9. A method according to claim 8 wherein the combination therapy, in addition to administration of the composition comprising the anti-S1P antibody, further comprises surgery.